Eyenovia Inc EYEN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if EYEN is a good fit for your portfolio.
News
-
Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities
-
Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings
-
Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
-
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals
-
Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th
-
Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-operative Inflammation and Pain Following Ocular Surgery
-
Eyenovia Announces FDA Approval of Redwood City as Commercial Manufacturing Facility
-
Eyenovia Gets FDA Approval for Mydcombi Ophthalmic Spray
Trading Information
- Previous Close Price
- $0.54
- Day Range
- $0.54–0.60
- 52-Week Range
- $0.50–5.85
- Bid/Ask
- $0.56 / $0.59
- Market Cap
- $27.65 Mil
- Volume/Avg
- 769,439 / 1.3 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 5,897.83
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 57
- Website
- https://www.eyenovia.com
Comparables
Valuation
|
Metric
|
EYEN
|
OCUL
|
TYRA
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.75 | 6.31 | 3.45 |
Price/Sales | 5,897.83 | 7.32 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
EYEN
OCUL
TYRA
Financial Strength
|
Metric
|
EYEN
|
OCUL
|
TYRA
|
|---|---|---|---|
Quick Ratio | 1.62 | 6.36 | 13.27 |
Current Ratio | 2.17 | 6.66 | 13.80 |
Interest Coverage | −10.79 | −6.47 | — |
Quick Ratio
EYEN
OCUL
TYRA
Profitability
|
Metric
|
EYEN
|
OCUL
|
TYRA
|
|---|---|---|---|
Return on Assets (Normalized) | −80.71% | −44.13% | −22.50% |
Return on Equity (Normalized) | −181.06% | −244.33% | −23.73% |
Return on Invested Capital (Normalized) | −83.80% | −63.64% | −27.79% |
Return on Assets
EYEN
OCUL
TYRA
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Whsdzchlt | Vxkns | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Yklypsw | Jsrhjv | $104.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Qkcjyhk | Fshyjg | $99.6 Bil | |
MRNA
| Moderna Inc | Zyrdzbtxh | Tyyj | $38.8 Bil | |
ARGX
| argenx SE ADR | Kvlxqhn | Yvsnv | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Kxxsjzpr | Ftnz | $21.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Mppsnsv | Rbmvsj | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Lnsbjvhzn | Kxvbz | $17.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Dxnmxnkcb | Msnwnjp | $12.4 Bil | |
INCY
| Incyte Corp | Rkfvbvtth | Rgvjm | $11.9 Bil |